Corporate Support
Sitemap

Features

Customer Services

Events

Terms of Use

Singapore
Malaysia

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,240.0
5.5 (0.17%)

 

  • STI Straits Times Index
    3,240.0
    5.5 (0.17%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,574.4
    -3.5 (-0.22%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,940.5
    -
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,976.5
    -84.2 (-2.75%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,343.5
    -483.7 (-2.03%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,133.2
    -110.9 (-1.78%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,246.1
    -21.1 (-0.93%)
    Index delayed 20 minutes
  • XAO XAO
    7,203.2
    4.2 (0.06%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 872.5M
  • Value: 729.1M
  • Rise: 113
  • Fall: 130
  • Unch: 575

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol

  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Medtecs Intl0.104-0.001
ThaiBev0.795+0.005
Rex Intl0.181+0.007
Spackman0.018+0.002
Golden Agri-Res0.225-
Genting Sing0.910-0.005
Joyas Intl0.003-
OEL0.023-0.001
YZJ Shipbldg SGD1.040-0.020
AusGroup^0.042+0.003

World Indices

World Indices
Name Last Change
Nasdaq 9,314.9 -87.6
HSI 27,940.5
HSCEI 10,969.3
Jakarta 6,133.2 -110.9
Nikkei 225 23,343.5 -483.7
SSE Comp 2,976.5 -84.2
Shanghai A 3,118.9 -88.2
Shanghai B 248.6 -8.9
PSE Comp 0.0
KOSPI 2,246.1 -21.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help

  • Factsheet

  • Print

CEL-SCI CORP CEL-SCI CORPORATION
Updated on 24 Jan 2020 (End of trading day)
Last (USD): 13.960 Change: -0.160 High: 15.000 Remarks: -
Change (%): -1.13 Low: 13.390
Open 14.510 Yesterday's Close 14.120000000000001
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 1,324,028 Cumulative Value
 
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -3.41015 Trailing EPS (USD) e -2.37089 NAV (USD) b 0.5499
PE a - Trailing PE f - Price / NAV b 25.3864
Dividend (USD) d - Cash In Hand (USD) g 0.9045 Issued & Paid-up Shares c 35,990,600
Dividend Yield (%) d - Price / Cash In Hand g 15.434 Treasury Shares h -
Beta - 75 Daysi 1.825 R-Squared - 75 Days(%)i 6.02 Market Cap (M) 130.331
Beta - 500 Daysi 1.303 R-Squared - 500 Days (%)i 2.41 Enterprise Value (M) 135.394
Piotroski F Score 3 Exchange Code CVM Par Value ( $ ) n.a.
52 Weeks Volatility (%) 102.75 Free Float (%) 93.7
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 27 Dec 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 29 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference CEL-SCI CORP NYSE American 130.331 - - 25.3864 -
Industry Biotechnology NYSE American 106.544 - - 4.0488 -
Local Peer NANOVIRICIDES INC NYSE American 532.958 - - 58.3967 -
Local Peer PFENEX INC NYSE American 262.113 - - 4.6945 -
Local Peer NAVIDEA BIOPHARMACEUTICALS INC NYSE American 223.846 - - -293.6170 -
Local Peer LINEAGE CELL THERAPEUTICS INC NYSE American 155.786 - - 1.3298 -
Local Peer MATINAS BIOPHARMA HOLDINGS INC NYSE American 135.199 - - 3.9816 -
Local Peer 22ND CENTURY GROUP INC NYSE American 108.926 - - 1.9695 -
Local Peer PALATIN TECHNOLOGIES INC NYSE American 106.671 2.982 2.887 1.1097 -
Local Peer SYNTHETIC BIOLOGICS INC NYSE American 70.856 - - 690.6250 -
Local Peer ISORAY INC NYSE American 46.005 - - 6.6155 -
Local Peer ARMATA PHARMACEUTICALS INC NYSE American 26.296 - - 1.4502 -
Local Peer IBIO INC NYSE American 25.897 - - -13.4135 -
Local Peer ORAGENICS INC NYSE American 22.380 - - 1.5646 -
Other Local Peers INDIA GLOBALIZATION CAPITAL INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), NOVABAY PHARMACEUTICALS INC (NYSE American), AIM IMMUNOTECH INC (NYSE American)
Global Peer AMGEN INC NASDAQ 134,041.969 15.969 16.616 12.2671 2.480
Global Peer CSL ASX 141,021.137 52.562 52.563 18.8452 0.854
Global Peer GILEAD SCIENCES INC NASDAQ 79,894.223 14.646 29.667 3.8776 3.659
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer VERTEX PHARMACEUTICAL NASDAQ 58,902.779 28.097 27.476 11.2123 -
Global Peer BIOGEN INC NASDAQ 50,188.138 11.327 9.302 3.5859 -
Global Peer ILLUMINA INC NASDAQ 46,978.260 56.874 48.282 10.5831 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 37,910.353 15.509 17.680 3.6090 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 27,376.752 86.636 25.562 5.7660 0.692
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 23,295.304 300.197 15.844 2.2470 -
Other Global Peers SEATTLE GENETICS INC (NASDAQ), SINO BIOPHARM (HKEx), WUXI BIO (HKEx), INCYTE CORPORATION (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), EXACT SCIENCES CORP (NASDAQ), BEIGENE (HKEx), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), 10X GENOMICS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), EXELIXIS INC (NASDAQ), REPLIGEN CORP (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), Lonza (SGX), GENSCRIPT BIO (HKEx), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), FIBROGEN INC (NASDAQ), 3SBIO (HKEx), AGIOS PHARMACEUTICALS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), ALLOGENE THERAPEUTICS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), NATERA INC (NASDAQ), ACCELERON PHARMA (NASDAQ), KODIAK SCIENCES INC (NASDAQ), UNIQURE N.V. (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), SYNTHORX INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), EPIZYME INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), ARVINAS INC (NASDAQ), XENCOR INC (NASDAQ), VIELA BIO INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), INSMED INC (NASDAQ), ALECTOR INC (NASDAQ), REGENXBIO INC (NASDAQ), ALPHAMAB-B (HKEx), HAOHAI BIOTEC (HKEx), LIGAND PHARMACEUTICAL INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), CORTEXYME INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), POLYNOVO LIMITED (ASX), COHERUS BIOSCIENCES INC (NASDAQ), NEXTCURE INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MESOBLAST LTD (ASX), FRONTAGE (HKEx), ENANTA PHARMACEUTICALS INC (NASDAQ), CKLIFE SCIENCES (HKEx), OPKO HEALTH INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), DERMIRA INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), AVITA MEDICAL LTD (ASX), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), XBIOTECH INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), VIVA BIOTECH (HKEx), RADIUS HEALTH INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), IMMUNOGEN INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), KADMON HLDGS INC (NYSE), ASCENTAGE-B (HKEx), CYTOKINETICS INC (NASDAQ), RETROPHIN INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), NANTKWEST INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), AVROBIO INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), ARDELYX INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), MACROGENICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), SINOMAB BIO-B (HKEx), AGENUS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), MERUS B V (NASDAQ), BELLUS HEALTH INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), TRANSLATE BIO INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), ASCLETIS-B (HKEx), RIGEL PHARMACEUTICALS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), ESSEX BIO-TECH (HKEx), COMPUGEN (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), PERSONALIS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), RECRO PHARMA INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), IVERIC BIO INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), LEE'S PHARM (HKEx), STEMLINE THERAPEUTICS INC (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), DPHARMA (Bursa), SPECTRUM PHARMACEUTICALS INC (NASDAQ), MEDICINOVA INC (NASDAQ), NEXT SCIENCE LTD (ASX), KAMADA (NASDAQ), GERON CORP (NASDAQ), TELIX PHARMACEUTIC (ASX), WAVE LIFE SCIENCES LTD (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), NOVAVAX INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), BBI LIFE SCI (HKEx), VBI VACCINES INC CDA (NASDAQ), AFFIMED N V (NASDAQ), SERES THERAPEUTICS (NASDAQ), IMV INC (NASDAQ), ATHERSYS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), XOMA CORP (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), GLYCOMIMETICS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), CHIASMA INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), CONTRAFECT CORP (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), ARAVIVE INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), VERASTEM INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), SAVARA INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), UNI-BIO GROUP (HKEx), RESAPP HEALTH LIMITED (ASX), PYC THERAPEUTICS LIMITED (ASX), ENZO BIOCHEM INC (NYSE), AVALON GLOBOCARE CORP (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), CHIMERIX INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), VACCINEX INC (NASDAQ), COHBAR INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), OTONOMY INC (NASDAQ), IMUGENE LIMITED (ASX), ACORDA THERAPEUTICS INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), SESEN BIO INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), TREVENA INC (NASDAQ), ORGENESIS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), EQUILLIUM INC (NASDAQ), INFLARX N V (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), SYNLOGIC INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), VERMILLION INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), IMMUTEP LTD (ASX), MICROBOT MEDICAL INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), NEWLINK GENETICS CORP (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), SOLIGENIX INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), ORTHOCELL LIMITED (ASX), KEZAR LIFE SCIENCES INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), CURIS INC (NASDAQ), CT ENTERPRISE (HKEx), T2 BIOSYSTEMS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), INMUNE BIO INC (NASDAQ), ADVAXIS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), RESTORBIO INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), EVOGENE LTD (NASDAQ), ZAFGEN INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), ALIMERA SCIENCES INC (NASDAQ), BIOSINO BIO-TEC (HKEx), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), OCUGEN INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), BIOCARDIA INC (NASDAQ), BIOTRON (ASX), SEELOS THERAPEUTICS INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), GENETIC TECHNOLOGIES (ASX), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), APTEVO THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), ANTEOTECH LIMITED (ASX), REGENT PACIFIC (HKEx), BIONOMICS LTD (ASX), MEMPHASYS LTD (ASX), TALI DIGITAL LIMITED (ASX), DARE BIOSCIENCE INC (NASDAQ), ATYR PHARMA INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), VAXART INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), CCP TECHNOLOGIES LTD (ASX), EXTRAWELL PHAR (HKEx), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), RHINOMED LIMITED (ASX), BIO-PATH HOLDINGS INC (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), IMMURON LIMITED (ASX), PRECIPIO INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), CELLMID LIMITED (ASX), CLEVELAND BIOLABS INC (NASDAQ), PATRYS LIMITED (ASX), ENDRA LIFE SCIENCES INC (NASDAQ), Suntar Eco-City^ (SGX), CONATUS PHARMACEUTICALS INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), TOCAGEN INC (NASDAQ), TROVAGENE INC (NASDAQ), BIOCEPT INC (NASDAQ), REGENEUS LTD (ASX), CYCLACEL PHARMA IN (NASDAQ), ADALTA LTD (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), HOLISTA COLLTECH LIMITED (ASX), ACHIEVE LIFE SCIENCE INC (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), SIENNA CANCER DIAGNOSTICS LTD (ASX), SENESTECH INC (NASDAQ), OPGEN INC (NASDAQ), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), SENECA BIOPHARMA INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), QT Vascular (SGX), LIVING CELL TECHNOLOGIES (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), HAO WEN HLDGS (HKEx), BENITEC BIOPHARMA LTD (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), BIOXYNE LIMITED (ASX), MEDIBIO LIMITED (ASX), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), MGRC (Bursa), SPHERIX INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), TBG DIAGNOSTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), AMPLIA THERAPEUTICS LTD (ASX), BPH ENERGY LIMITED (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+3.930
+39.18 %
10 Days -+4.620
+49.46 %
20 Days -+5.300
+61.20 %
Medium Term Return 3 Months -+6.770
+94.16 %
6 Months -+6.230
+80.60 %
1 Year -+11.210
+407.64 %
Long Term Return 2 Years -+11.800
+546.30 %
3 Years -+10.960
+365.33 %
5 Years --53.540
-79.32 %
Annualised Return Annualised --
-27.03 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 2.367 - 15.000 Change From 1 Year Low +11.593 % Change From 1 Year Low (%) +489.83
Change From 1 Year High -1.040 % Change From 1 Year High (%) -6.93
2 Years Range 0.817 - 15.000 Change From 2 Years Low +13.143 % Change From 2 Years Low (%) +1609.74
Change From 2 Years High -1.040 % Change From 2 Years High (%) -6.93
5 Years Range 0.817 - 27.250 Change From 5 Years Low +13.143 % Change From 5 Years Low (%) +1609.74
Change From 5 Years High -13.290 % Change From 5 Years High (%) -48.77
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Historical Price Data

Date Open High Low Close Volume VWAP
24 Jan 2020 14.510 15.000 13.390 13.960 1,324,028 -
23 Jan 2020 12.760 14.170 11.800 14.120 1,519,827 -
22 Jan 2020 13.000 14.410 13.000 13.740 3,044,978 -
21 Jan 2020 10.040 12.380 10.040 12.330 1,962,798 -
17 Jan 2020 9.600 10.350 9.550 10.030 1,301,124 -
16 Jan 2020 8.960 9.850 8.960 9.820 910,347 -
15 Jan 2020 8.940 9.230 8.850 9.100 642,492 -
14 Jan 2020 9.830 9.900 8.830 9.090 1,368,944 -
13 Jan 2020 8.300 9.990 7.850 9.340 2,481,793 -
10 Jan 2020 7.560 7.780 7.360 7.780 655,202 -
09 Jan 2020 7.610 7.880 7.510 7.540 892,937 -
08 Jan 2020 8.480 8.680 7.760 7.950 1,139,705 -
07 Jan 2020 8.840 8.920 8.520 8.610 827,108 -
06 Jan 2020 8.810 9.000 8.790 8.940 644,335 -
03 Jan 2020 8.770 9.150 8.770 9.020 574,816 -
02 Jan 2020 8.910 9.103 8.787 9.090 627,638 -
31 Dec 2019 8.560 9.150 8.560 9.150 1,061,297 -
30 Dec 2019 8.500 8.711 8.310 8.660 490,839 -
27 Dec 2019 8.350 8.720 8.160 8.580 541,583 -
26 Dec 2019 8.860 9.000 8.340 8.460 813,030 -
24 Dec 2019 8.910 9.310 8.800 8.950 1,153,315 -
23 Dec 2019 9.190 9.740 9.050 9.550 948,934 -
Summary
Current 2 Weeks
(10 Jan 2020 to 24 Jan 2020)		 7.560 15.000 7.360 13.960 15,211,533 -
Previous 2 Weeks
(26 Dec 2019 to 09 Jan 2020)		 8.860 15.000 7.360 7.540 7,613,288 -
4 Weeks from
(26 Nov 2019 to 24 Dec 2019)		 7.420 15.000 7.260 8.950 10,783,919 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.